Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

NCT06466798 is registered in ClinicalTrials.gov with Jeffrey Treiber as lead sponsor.

NCT NCT06466798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06466798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
Lead sponsor
Jeffrey Treiber
Phase
Phase 1
Overall status
Withdrawn
Start date
July 15, 2024
Completion date
July 1, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cns malignancies, recurrent ependymoma, recurrent medulloblastoma